Pharmaceutical handling of the chiral ester hydrochloride designated D-(+)-methyl α-(2-thienylethylamino)(2-chlorophenyl)acetate hydrochloride proceeds from a crystalline salt of molecular formula C15H17Cl2NO2S and molar mass 346.27 g/mol. The molecule contains a secondary amine, a methyl ester, a thiophene ring, and a 2-chlorophenyl substituent; the hydrochloride counterion gives the solid a theoretical chloride content of 20.48% w/w and generally improves aqueous dispersibility relative to the free base. Product grades are defined by route of administration and downstream unit operation: oral solid-dose grade for tablet and capsule, granulated grade for roller compaction or wet granulation, and injectable grade with reduced bioburden, endotoxin, and particulate burden. Each grade shares the same molecular identity and chiral descriptor; model codes are assigned by the manufacturer and must be reconciled with the approved Drug Master File or Certificate of Analysis. No harmonized pharmacopoeial monograph assigns acceptance criteria for this exact molecule, so release specifications rely on the applicant’s validated analytical methods and a qualified reference standard.

What Solid-Form and Impurity Profiling Controls Precede Tablet and Capsule Use?

Before dry blending, the vendor CoA should report solid-state identity by X-ray powder diffraction under Ph. Eur. 2.9.33 and infrared absorption spectrophotometry under Ph. Eur. 2.2.24. Differential scanning calorimetry is used as a screening indicator; variation in the endothermic peak beyond the validated range may indicate solvate formation or residual solvent retention. Particle-size distribution is measured by laser diffraction under Ph. Eur. 2.9.31, with d10, d50, and d90 values used to set direct-compression or granulation decisions. For low-dose tablet and capsule formulations where the hydrochloride is present at 5 mg or less per unit, a geometric premix with microcrystalline cellulose and crospovidone at 2–5% w/w is prepared in a low-shear tumble blender; blend uniformity is verified by stratified sampling under the approved validation protocol. Published data for this specific configuration are limited; therefore the actual d50 range and polymorphic fingerprint should be taken from the supplier’s CoA rather than from a general monograph.

On high-speed rotary tablet presses equipped with paddle feeders, powders with a large fine fraction below 10 µm can increase feed shoe segregation and weight variability; pre-milling with a spiral jet mill or pin mill may be required to control the fine tail and improve flow. When roller compaction is selected, flakes are milled through a screen of 0.8–1.25 mm and blended with croscarmellose sodium; granule friability is checked by sieve analysis. For wet granulation, the hydrochloride may be dissolved in the binder solution, but aqueous granulation at elevated pH can promote methyl ester hydrolysis; therefore the granulating fluid is maintained at pH ≤6.0 unless forced-degradation data show that a higher pH is acceptable. Drying in a fluid-bed dryer at inlet air temperature not exceeding 55°C and final loss on drying ≤2.0% w/w is used when dictated by the formulation; these values are starting points and must be confirmed by stability data for the specific ester. Capsule filling on an intermittent-motion machine with dosator systems may require the powder blend to have a flow function coefficient above 4.0 as measured by a ring shear cell; otherwise, a granular grade with increased bulk density is substituted.

When Terminal Sterilization of an Injectable Solution Is Unacceptable

Terminal moist-heat exposure at 121°C for 15 min should be rejected if forced-degradation testing shows total degradation above 0.5% or if any unspecified impurity exceeds the ICH Q3B identification threshold. Because the molecule contains a methyl ester, hydrolytic ester cleavage can occur in phosphate-buffered injection vehicles at high temperature; injectable grade may instead be processed by aseptic filtration through a 0.22 µm membrane and filled in an ISO 14644-1 Class 5 environment under EU GMP Annex 1 or FDA 21 CFR 210/211 conditions. If a lyophilized cake is required, the freeze-drying cycle includes annealing at −20°C to −5°C for 2–4 h, primary drying at shelf temperature −10°C to 0°C under 0.1–0.3 mbar, and secondary drying at 25–35°C until residual moisture by Karl Fischer is within the approved limit. Container closure integrity is verified by dye ingress or helium leak according to Ph. Eur. 3.2.1 and Ph. Eur. 3.2.9.

Chiral Purity and Related-Substance Profiling by Liquid Chromatography

The enantiomeric identity of D-(+)-methyl α-(2-thienylethylamino)(2-chlorophenyl)acetate hydrochloride is confirmed by chiral HPLC under Ph. Eur. 2.2.29, typically with a cellulose tris(3,5-dimethylphenylcarbamate) or amylose tris(3,5-dimethylphenylcarbamate) stationary phase. The undesired enantiomer is reported as an area percent relative to the main peak; a qualified reference standard is required because no pharmacopoeial chemical reference substance is available. For related substances, reversed-phase HPLC with a C18 column of 5 µm particle size and a mobile phase containing phosphate buffer at pH 3.0–4.0 and acetonitrile is used, with detection at 220 nm or 235 nm after method validation. The system suitability criteria include resolution between the active and its known process-related impurities or hydrolyzed acid degradation product, tailing factor ≤2.0, and relative standard deviation ≤1.0% for five replicate injections. Forced degradation under acid, base, peroxide, heat, and light is performed per ICH Q1A and Q1B to establish stability-indicating capability.

Compared with the free base, the hydrochloride salt reduces the need for pH adjustment in aqueous injection compounding because the protonated amine is more readily wetted and dissolved in Water for Injection. The free base may be retained for nonaqueous granulation or for downstream chemistry where chloride would interfere with a subsequent alkylation or coupling step. Compared with the racemate, the D-(+) salt requires chiral chromatography or enantioselective synthesis and carries a higher impurity-control burden because the opposite enantiomer is controlled as an impurity. Compared with other counterions such as hydrobromide or mesylate, the chloride salt avoids the introduction of additional organic ion residues but may require stainless steel contact surfaces with passivated 316L or higher alloys in high-moisture granulation owing to chloride-associated pitting. Published data for this specific configuration are limited; therefore direct comparisons of powder flow and compactibility should be generated using a shear cell tester and a compaction simulator rather than inferred from molecular properties.

Residual Solvent and Elemental Impurity Limits Follow ICH Q3C and ICH Q3D

Residual solvent analysis by headspace gas chromatography under Ph. Eur. 2.4.24 must demonstrate absence of Class 1 solvents and compliance with ICH Q3C limits for Class 2 solvents such as dichloromethane or N,N-dimethylformamide if used in synthesis. Elemental impurities are profiled by ICP-MS or ICP-OES using ICH Q3D; for an injectable grade, the permitted daily exposure for cadmium, lead, arsenic, mercury, and other element classes is derived from the maximum daily dose and the route of administration. Because the molecule contains thiophene sulfur and aromatic chlorine, method validation for elemental impurities should include recovery experiments on spiked digestion matrices to rule out chlorine-related interference. Container closure systems should conform to Ph. Eur. 3.2.1 for glass containers and Ph. Eur. 3.2.9 for rubber stoppers when injectable product is supplied.